Pfizer AB, 113 63 Stockholm, Sweden.
Fondazione Toscana Life Sciences, 53100 Siena, Italy.
Future Oncol. 2024;20(20):1385-1392. doi: 10.1080/14796694.2024.2351352. Epub 2024 Jul 26.
Assess the time-to-treatment discontinuation (TTD) and overall survival (OS) in a Swedish metastatic renal cell carcinoma (mRCC) nationwide cohort who received second-line axitinib. Retrospective analysis of 110 patients with mRCC treated with second-line axitinib in Sweden (2012-2019). Patients included in the study received axitinib after mainly first-line sunitinib or pazopanib. The median (95% CI) TTD of patients who received second-line axitinib was 5.2 (3.7-6.1) months with 6 (5.5%) patients still receiving treatment at the time of analysis. Median (95% CI) OS was 12.2 (7.7-14.2) months. The results are consistent with previous findings in mRCC and add to the evidence demonstrating efficacy of second-line axitinib, after failure of a prior anti-angiogenic therapy in a real-world setting. NCT04669366 (ClinicalTrials.gov).
评估在接受二线阿昔替尼治疗的瑞典转移性肾细胞癌（mRCC）全国队列中患者的治疗终止时间（TTD）和总生存期（OS）。对瑞典 110 例接受二线阿昔替尼治疗的 mRCC 患者（2012-2019 年）进行的回顾性分析。研究纳入的患者在接受二线阿昔替尼治疗前主要接受了一线舒尼替尼或帕唑帕尼治疗。接受二线阿昔替尼治疗的患者 TTD 的中位数（95%CI）为 5.2（3.7-6.1）个月，在分析时仍有 6（5.5%）例患者在接受治疗。中位（95%CI）OS 为 12.2（7.7-14.2）个月。这些结果与 mRCC 中的先前发现一致，并在真实环境中在前一种抗血管生成治疗失败后，增加了二线阿昔替尼疗效的证据。NCT04669366（ClinicalTrials.gov）。
